Navigation Links
GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
Date:11/29/2011

IRVINE, Calif., Nov. 29, 2011 /PRNewswire/ -- GeneTex, a leading manufacturer of antibodies and antibody-related reagents, is pleased to announce that they will be launching a new line of antibodies against Hice1 and Hec1. Both of these targets are key players in spindle assembly.

(Photo:  http://photos.prnewswire.com/prnh/20111129/LA13485-a)

(Logo:   http://photos.prnewswire.com/prnh/20111129/LA13485LOGO-b)

Hice1 is a novel microtubule-associated protein that is required for the maintenance of spindle integrity and chromosomal stability, and the phosphorylation of Hec1 by Nek2 kinase has been shown to modulate chromosome alignment and signaling of the spindle assembly checkpoint. The interaction between Hec1 and Hice also contributes to mitotic centrosomal microtubule growth for proper spindle assembly.

GeneTex's new product line will include a phospo Ser 55 Hec1 antibody, a non-phospho Ser 55 Hec1 antibody, a phospo Ser 76/77 Hec1 antibody, a non-phospho Ser 76/77 Hec1 antibody, a phospo Ser 165 Hec1 antibody, a non-phospho Ser 165 Hec1 antibody, a phospho Ser 19/20 Hice1 antibody, a non-phospho Ser 19/20 Hice1 antibody, as well as corresponding blocking peptides. A complete listing of Hec1 and Hice1 antibodies is available at http://www.genetex.com/Hec1_Hice1.

"I am thrilled to be working with GeneTex to bring these antibodies to a wider group of researchers," said Dr. Guikai Wu, a researcher from the University of California, Irvine who developed these antibodies and has recently published his results in Molecular and Cellular Biology ("Hice1, a Novel Microtubule-Associated Protein Required for Maintenance of Spindle Integrity and Chromosomal Stability in Human Cells") and Molecular Biology of the Cell ("Hec1 Contributes to Mitotic Centrosomal Microtubule Growth for Proper Spindle Assembly through Interaction with Hice1"). "These are excellent antibodies that have worked in every application that I have tried."

The study of spindle assembly has widespread applications, as this process is critical for efficient mitotic progression and accurate chromosome segregation. Errors in this process often lead to structural and functional aberrations that result in the promotion of segregation errors and aneuploidy, a hallmark of most cancers.

GeneTex will be launching one of the largest collections of Hec1 and Hice1 antibodies that have been validated for western blotting, immunofluorescence (ICC/IF), immunohistochemistry (IHC) and other applications. Almost all of the antibodies in the line are antigen-affinity purified, which results in higher quality antibodies for research. GeneTex will also be offering smaller-sized vials of their zebrafish antibodies, allowing researchers the flexibility to try new antibodies at a much lower cost.

For additional information on GeneTex's new line of Hec1 and Hice1 antibodies, call toll-free 877-GENETEX (436-3839) or visit http://www.genetex.com/Hec1_Hice1.

About GeneTex:

GeneTex is an antibody company that was founded by scientists in 1997. They strive to produce the highest quality antibodies and reagents. Their primary antibodies and secondary antibodies are created through a process involving extensive research, development and validation.  GeneTex has over 45,000 primary antibodies in its catalog that are all backed by a 100% Satisfaction Guarantee.  

Contact:

GeneTex
877-436-3839
info@genetex.com


'/>"/>
SOURCE Genetex
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GeneTex Antibody Company to Launch a Line of New Zebrafish Primary Antibodies
2. Ventana Medical Systems, Inc. Receives First FDA 510(k) Clearance for H. pylori Antibody
3. ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development
4. Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb
5. BioLegend Releases Brilliant Violet 421™ Antibody Conjugates For Advanced Flow Cytometry Applications.
6. Amgen and Xencor Enter Option Deal to Co-Develop Xencors Novel Antibody for Autoimmune Diseases
7. Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors
8. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
9. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
10. Armed antibody triggers remissions for Hodgkins lymphoma
11. Micromet to Provide Update on BiTE Antibody Development Programs at Upcoming Medical Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... ... 23, 2017 , ... David Nolte, PhD accepted Purdue University’s ... Purdue Research Park of West Lafayette, Indiana. , The top commercialization award ... and success with, commercializing discoveries from Purdue research. “This award is truly an ...
Breaking Biology Technology:
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
Breaking Biology News(10 mins):